Rebecca Mather
About Rebecca Mather
Rebecca Mather is a Senior Scientist specializing in T Cell Process Development at Adaptimmune, where she has worked since 2019. She focuses on developing novel therapies for aggressive, treatment-resistant cancers and has a strong background in cell and molecular techniques.
Work at Adaptimmune
Rebecca Mather has been employed at Adaptimmune since 2019, serving as a Senior Scientist in T-cell Process Development. In this role, she focuses on the process development of autologous T-cell therapies. Her work is integral to advancing the company's initiatives in developing innovative cancer treatments. Mather has contributed to ensuring that the Cell PD team meets project goals and objectives, demonstrating her commitment to the organization's mission.
Education and Expertise
Rebecca Mather earned her Doctor of Philosophy (Ph.D.) from the University of Portsmouth, where she researched the deacetylation of GD3A as a potential therapeutic strategy for paediatric medulloblastoma from 2012 to 2016. Prior to her Ph.D., she completed a Bachelor's Degree in Pharmacology at the same institution from 2009 to 2012. Mather possesses expertise in a wide variety of cell and molecular techniques, which supports her current research and development efforts.
Background
Before joining Adaptimmune, Rebecca Mather worked as a Postdoctoral Research Associate at The Open University from 2016 to 2019. This position was funded by Cancer Research UK and took place in Milton Keynes, United Kingdom. During her tenure, she developed skills in managing teams in a matrix manner and coordinating goal-driven activities, which are essential for her current role.
Achievements
Rebecca Mather has received recognition for her contributions to the Cell PD team at Adaptimmune, including spot awards for her achievements in ensuring that project goals and objectives are met. This acknowledgment reflects her dedication and effectiveness in her role as a Senior Scientist, particularly in the context of developing novel therapies for aggressive, treatment-resistant cancers.